PRGO

Perrigo's stock price has experienced notable fluctuations in the past six months, declining 36.55% over the past year and 41.94% over the last 12 months, but recently rebounding with a 40.74% increase in the past month and a 32.29% gain over the past three months. In Q1 2026, Perrigo reported a 7.2% year-over-year decline in net sales due to lower seasonal cough and cold incidence and reduced retailer inventory levels, yet maintained its full-year outlook. For Q2 2026, the company announced diluted earnings per share of $0.63, significantly up from the prior year and surpassing analyst estimates, with revenue of $1.02 billion meeting expectations, leading to a 23.1% gain in shares the day after and a reaffirmation of its full-year outlook anticipating a stronger second half. Other key events include the completion of its Dermacosmetics business sale for approximately €306 million, intended for debt reduction, and ongoing strategic reviews of its Infant Formula and Oral Care businesses. Perrigo also paid a quarterly dividend of $0.29 per share with an ex-dividend date of August 28, 2026, and faced news in late August 2026 that defendants in a lawsuit asked the court to dismiss investor claims.